The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
MUC1 oncoprotein is a druggable target in human prostate cancer cells
Open accessAbstract
Human prostate cancers are dependent on the androgen receptor for their progression. The MUC1 heterodimeric oncoprotein is aberrantly overexpressed in prostate cancers; however, it is not known if MUC1 is of functional importance to these tumors. To assess dependence on MUC1, we synthesized an inhibitor, designated GO-201, which interacts directly with the MUC1-C subunit at its oligomerization domain. Treatment of MUC1-positive DU145 and PC3 prostate cancer cells with GO-201, and not an altered version, resulted in inhibition of proliferation. GO-201 also induced necrotic cell death that was associated with increases in reactive oxygen species, loss of mitochondrial transmembrane potential, and depletion of ATP. By contrast, GO-201 had no effect against MUC1-negative LNCaP, CWR22Rv1, and MDA-PCa-2b prostate cancer cells. Significantly, GO-201 treatment of DU145 and PC3 xenografts growing in nude mice resulted in complete tumor regression and prolonged lack of recurrence. These findings indicate that certain prostate cancer cells are dependent on MUC1-C for growth and survival and that directly targeting MUC1-C results in their death in vitro and in tumor models. [Mol Cancer Ther 2009;8(11):3056–65]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · cited 7×
“In concert with these responses, targeting of MUC1-C with GO-201 was also associated with depletion of ATP, which is associated with random DNA degradation and loss of cell membrane integrity in necrotic cell death (44).”
BackgroundInfluentialThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“cells has been further supported by the targeting of AR function in in vitro and animal tumor models (29, 30).”
BackgroundScher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Linking β-Catenin to Androgen-signaling Pathway
Yang, F., Li, X., Sharma, M., Sasaki, C. Y., Longo, D. L., Lim, B., & Sun, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111962200 · Cited by 342
Cited by
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493
Mucins in cancer: function, prognosis and therapy
Kufe, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2761 · Cited by 1,396
Self-citationKufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2012.158 · Cited by 437
Self-citationMucins in pancreatic cancer and its microenvironment
Kaur, S., Kumar, S., Momi, N., Sasson, A. R., & Batra, S. K. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.120 · Cited by 301
Dhanisha, S. S., Guruvayoorappan, C., Drishya, S., & Abeesh, P. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.006 · Cited by 194
Metadata
- Authors
- Joshi, M. D., Ahmad, R., Yin, L., Raina, D., Rajabi, H., Bubley, G., Kharbanda, S., & Kufe, D.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2009-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 3056-3065
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2118642421
- Cited by
- 72
- References
- 7
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MUC1 oncoprotein is a druggable target in human prostate cancer cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0646
- The paper
- Joshi, M. D., Ahmad, R., Yin, L., Raina, D., Rajabi, H., Bubley, G., Kharbanda, S., & Kufe, D. (2009). MUC1 oncoprotein is a druggable target in human prostate cancer cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.